MDACC Study No:2012-1107(2010-0837LYMPHOMA) ( NCT No: NCT01804686)
Title:A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
Principal Investigator:Michael Wang
Treatment Agent:PCI-32765
Study Status:Open
Study Description:The goal of this clinical research study is to learn if PCI-32765 continues to
be safe and effective when given long-term (beyond your previous PCI-32765
treatment) to treat lymphoma.

PCI-32765 is designed to block an enzyme that can cause cancer cells to grow.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase III
Treatment Agents:PCI-32765
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Janssen Research & Development, LLC
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael Wang
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults